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At a glance commentary 
 
Scientific knowledge on the subject: 
Epidemiological data have suggested a link between respiratory viral and invasive and severe 
respiratory bacterial infections, while animal studies using wild and attenuated influenza 
strains have shown increases in density of S. pneumoniae and S. aureus in the nasopharyngeal 
mucosa. There is no experimental evidence on this subject in humans. 
 
What this study adds to the field: 
This randomized trial provides evidence that administration of live attenuated influenza 
vaccine to healthy children, after a short delay, increases the colonization density with S. 
pneumoniae in individuals carrying this bacterial species at the time of vaccination. It may also 
transiently increase rates of nasal colonization with H. influenzae. Comparison of pre- and post-
vaccine samples by multivariate analysis confirms these findings and suggests that vaccination 
may also transiently increase the density of M. catarrhalis amongst carriers. 
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Abstract 
Rationale Viral infections of the upper respiratory tract may influence the commensal 
nasopharyngeal bacteria. Changes in the bacterial niche could affect transmission dynamics. 
Attenuated vaccine viruses can be used to investigate this empirically in humans.  
Methods We used trivalent Live Attenuated Influenza Vaccine (LAIV) to evaluate the effects of 
viral infection on bacterial carriage and density of S.pneumoniae, M.catarrhalis, H.influenzae 
and S.aureus. 151 healthy children were randomized 1:1 to receive the vaccine starting either 
at recruitment (n=74) or 28 days later (n=77) in a stepped wedge fashion, allowing 
comparisons between recipients and non-recipients as well as whole-group comparisons pre- 
and post- vaccination. Bacterial carriage and density were determined using qPCR assays.  
Measurement & Main Results 151 children were recruited, 77 in the LAIV group and 74 
controls. LAIV recipients (n=63 analysed) showed an apparent transient increase in 
H.influenzae carriage but no further significant differences in carriage prevalence of the four 
bacterial species compared to controls (n=72 analyzed). S.pneumoniae density was 
substantially higher in vaccine recipients (16687 vs 1935 GC/ml) 28 days after the first dose 
(p<0.001).  Whole-group multivariable analysis (pre-vaccine, after one dose and after two 
doses) also showed increases in density of other species and H. influenzae carriage prevalence.  
Conclusion In the absence of any safety signals despite widespread use of the vaccine, these 
findings suggest that bacterial density and thus, transmission rates amongst children and to 
other age groups may rise following attenuated influenza infections without associated clinical 
disease. LAIV could therefore be used as an experimental tool to elucidate the dynamics of 
transmission of nasopharyngeal bacteria. 
Word count: 259 
Key words: LAIV, Bacterial colonization, Children, Bacterial density 
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Introduction 
Pneumococcal conjugate vaccines are effective principally through population-wide effects on 
carriage and transmission(1). Despite this, the biology of colonization and determinants of 
transmission remain poorly understood. Evidence from both animals(2) and humans(3) 
suggests that respiratory viral infections can affect upper respiratory tract (URT) bacteria but 
the relevance of experiments in animal models to humans is uncertain and deductions about 
causation are difficult from observational studies. Studies from our group and others have 
shown that presence and colonization density of commensal bacteria of the nasopharynx (NP) 
is associated with symptoms of rhinitis and presence of respiratory viruses(4, 5).  
Live attenuated intranasal influenza vaccine (LAIV) was licensed in Europe in 2012 for children 
aged 2-18 years and until 2014 (when a second B strain was added) consisted of three 
replication competent viruses (two type A strains and one type B) attenuated by recombination 
of wild-type and attenuated donor viruses(6) and cold-adaptation through passages of 
progressively lower temperature in eggs(7). The vaccine viruses induce a broad cell mediated 
as well as local mucosal antibody responses(8) and replicate well at the lower temperatures of 
the upper respiratory mucosa but poorly in the lower airways or systemic circulation(9). LAIV is 
well tolerated, safe and effective in preventing culture/PCR proven influenza in children(10, 11) 
among whom flu is a common and sometimes serious infection. However, when compared to 
trivalent inactivated influenza vaccine (TIV), higher rates of medically significant wheezing were 
observed during the second to fourth weeks post-vaccination in children 6-23 months of age 
after 1st dose of vaccine (5.9% in LAIV recipients vs 3.8% in TIV recipients as shown in figure 3 in 
supplemental material from Belshe et al(12)). In addition, increased all-cause hospitalisation in 
children aged 6-11 months within 180 days of vaccination (6.1% in LAIV recipients vs 2.6% in 
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TIV recipients)(11), was observed, leading to restriction of licensure to children aged two years 
and older(13, 14). The pathophysiology of these adverse events is not understood.  
 
Mina et al. found a transient increase in density and delayed clearance of NP Streptococcus 
pneumoniae and Staphylococcus aureus in a mouse model, after administration of either a 
single, cold-adapted live attenuated influenza virus strain or wild-type (WT) influenza virus. No 
clinical disease was seen in animals given attenuated virus although up to 5% weight loss was 
observed if S. pneumoniae was present before vaccination(15). Thus both WT and attenuated 
influenza infection could influence bacterial load in the human NP although extrapolation to 
humans and LAIV should be done with caution.  
Demonstration of a similar effect in humans might help elucidate the relationship between 
respiratory viral infections and carriage prevalence and density dynamics of NP bacteria. The 
availability of LAIV which induces a mild URT infection without significant clinical illness offers 
an opportunity to undertake randomized interventional experimental studies in humans to 
explore this.  
 
Real‐time quantitative PCR (qPCR) can enumerate bacterial species-specific gene copies and 
thus both viable and non-viable bacteria in biological samples over wide concentration ranges 
with less effort and expense than conventional quantitative plate cultures. Using qPCR, we 
recently described upper respiratory bacterial density ranges as wide as 6 orders of magnitude 
in healthy children(16). Such differences may result in wide variation in efficiency of onward 
transmission amongst carriers. Although alternatives exist, nasopharyngeal swabbing is the 
most widely used method to sample the nasal flora, is easy to perform and reasonably well 
accepted by children. 
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To explore the effect of LAIV on carriage rates and density of four bacterial species which 
commonly colonize the human NP, we recruited 151 children to a prospective randomized 
study comparing vaccinated and unvaccinated children at one and four weeks post-vaccine and 
colonization before and after vaccination in the whole group. At the time of the study, no 
routine influenza immunization was being offered to healthy children in the UK.  
Some of the results of this study have been previously reported in the form of an abstract(17). 
 
Methods 
Study design  
This was a cohort stepped wedge study of a Live Attenuated Influenza Vaccine (LAIV) 
containing three (two A and one B) influenza strains, in children undertaken in 10 day care 
centers (DCC) in Bristol UK. 
 
Participants and randomization 
Children aged 2-4 years attending the DCC were eligible to participate. We attempted to 
provide written information sheets with an invitation to take part in the study to parents of all 
of the 659 eligible children in the ten DCCs; we were able to make contact with 80% of the 
parents and invite them to take part in the study between September 3 and October 15 2012.  
Only children for whom the vaccine was contraindicated were excluded (figure 1).  Informed 
consent was obtained for all enrolled subjects.  On enrolment, children were individually 
randomized [1:1] within nurseries using the BRTC electronic randomization system (Bristol 
Randomised Trials Collaboration, School of Social and Community Medicine, University of 
Bristol) by the study team, to receive the vaccine at day 0 (visit (V) 1) and on or around day 28 
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(V3) (LAIV group) or on or around day 28 (V3) and day 56 (V5) (control/ late vaccine group) 
with additional swabbing visits (V2 & V4) on or around days 7 and 35, respectively. A small 
number of children who had received inactivated influenza vaccine in either of the previous 
two seasons received only the first LAIV dose in the study (figure 1). If the child refused 
vaccination, NP swabbing only was attempted.  Laboratory staff were blinded to the 
intervention assignment during analysis. 
 
Intervention and procedures 
Vaccine doses were given intra-nasally following monitored cold chain storage and after 
medical assessment of each subject. Following immunization, children were observed for 30 
minutes. At all study visits, which were conducted at the DCCs between October 2012 and 
February 2013, a fine tip pediatric NP swab (Peel Pouch Dryswab™ Medical Wire & Equipment, 
Wiltshire, UK) was taken. For the swabbing procedure, the child was seated comfortably with 
the head slightly extended. The swab was inserted horizontally until resistance was met when 
the swab was retracted with a slight twisting action along the axis of the shaft and inserted into 
a 2ml tube prefilled with 1.5ml of Skim milk-Tryptone-Glucose-Glycerol (STGG) broth which 
was labelled with a random number to blind laboratory analysis. The records, linking the study 
participant and visit numbers with the blinding numbers were kept in a locked facility until 
after the completion of laboratory analysis. Tubes were held at 0-4°C until transferred to 
storage at -80°C within 4 hours of collection.  At the time of collection of each swab, severity of 
any rhinitis symptoms was recorded ("SNOT score" 0-3 as previously reported(4) and described 
in the online supplement).  
 
Laboratory analysis 
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Nucleic acid was extracted from all samples using the Virus/Pathogen mini kit® from QIAGEN 
(CA, USA) yielding 110µl extracts from 300µl STGG broth. These were stored at -80°C. 
Monoplex qPCR assays were used to detect S. pneumoniae, Moraxella catarrhalis, 
Haemophilus influenzae and S. aureus(16). The cycle threshold (Ct) value to define detection 
was set at ≤35 cycles. For density values, Ct values were converted into gene copies (GC)/ml 
using standard curves(16). qPCR assays for adenovirus, bocavirus, influenza (A and B), 
respiratory syncytial virus, rhinovirus, human metapneumovirus, parainfluenza (type 1-3), 
parechovirus, coronavirus (229E, OC43, NL63) and enterovirus were performed using methods 
described previously(4, 18). In addition, an assay for coronavirus HKU1 (online supplement, 
table E1) was used. 
 
Outcomes 
The primary endpoint was a comparison of the proportion of children positive for S. 
pneumoniae one week after a first dose of LAIV compared with the control group.  Additional 
planned endpoints included similar comparisons for M. catarrhalis, H. influenzae or S. aureus at 
one and four weeks after LAIV, of the density of all four species after the same intervals, both 
singly and combined and comparisons of the proportions of subjects positive and of carriage 
density for the four species before and after one or two doses of LAIV over all study visits both 
in all children studied and in those who either were or were not carriers of each species at the 
first visit. Exploratory and descriptive analyses, respectively, were also done with respect to 
rhinitis symptom scores and presence of respiratory viral nucleic acid in samples.  
 
Statistical analysis 
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Statistical analyses were done using Stata® version 12.0 (StataCorp, College Station, Texas).  To 
assess balance at randomization, differences characteristics were analyzed using Pearson's 
χ2 test and t-tests when appropriate.  We estimated the odds ratio (ORs) of carriage for each 
bacterial species in the early vaccine group compared to the control (late vaccine) group at V2 
and V3 post enrolment using logistic regression, including a fixed effect for vaccine group and a 
random effect (intercept) for nurseries, to allow for between-nursery variability.  We also 
estimated the ORs of carriage after one and two doses of LAIV (i.e. children contributed 
measurements before and after their vaccination) using logistic regression adjusting for 
confounders (detailed in footnotes to tables 4 and 5), with random effects (intercept) for 
nurseries and children to allow for repeated measures on the same individuals and between-
nursery variability.  We estimated the difference in mean density (GC/ml) of bacteria in those 
children positive for carriage (at baseline and the visit of interest) using gamma regression 
(because GC/ml were positively skewed), including the same fixed and random effects as for 
the odds of carriage analysis.  We modelled the effect of the vaccine from one visit after the 
vaccine was administered.  Analyses were done on the modified intention-to-treat (MITT) 
population, which included all enrolled participants who provided an assessable swab sample 
irrespective of whether they actually received the vaccine doses. Analyses were undertaken 
using gllamm program in Stata(19-21). 
 
Trial registration 
Trial registration was initiated (Eudract nr: 2011-002964-25) but owing to regulatory authority 
determination that this was not an IMP trial, since the vaccine was licensed for this age group, 
could not be completed. 
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Role of the funding source   
The funding bodies for the study had no role in the study design, data collection, data analysis, 
data interpretation or writing or approval of the manuscript. All authors had full access to all 
the data in the study and the corresponding author had responsibility for submitting the 
manuscript for publication. 
 
Ethical approval 
The study was approved by the UK National Research Ethics Service – Central Bristol 
Committee (ref nr. 11/SW/0186) and responsibility for governance oversight taken by the 
University of Bristol, UK. 
 
Results 
A consort diagram detailing screening, enrolment, randomization, loss to follow up and 
completion is shown in figure 1 (see details by nursery in online supplement table E2). A total 
of 125 children completed the vaccination protocol and 120 completed all visits (six withdrew 
before or at the time of the first visit, two departed from the area during the study and the 
others refused sampling repeatedly). The number of subjects recruited in each DCC ranged 
from 4 to 29. The median number of days after 1st vaccine dose at V2 sampling was 7 for both 
groups (range 5-26) and, for V3, 28 (27-43) and after the 2nd were (V4) 7 (6-16) and (V5) 28 (21-
48). The control (late vaccine) group had a higher mean number of siblings, but otherwise the 
groups were similar following randomization (table 1). There was no evidence to suggest a 
difference in antibiotic use between the groups at baseline (3/70 in vaccine group and 1/72 in 
controls), V2 (1/66 and 2/69) or V3 (3/65 and 3/72, respectively).    
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Virology results for the whole study period 
Respiratory viral nucleic acid was detected (CT≤35) in 216/670 samples (from 144 children) 
among which 37 samples had more than one virus. Rhinovirus was the most frequently 
detected (16.8%), followed by coronavirus (4.4%), parainfluenza virus (3.3%), bocavirus (3.1%), 
enterovirus (3.1%) and respiratory syncytial virus (2.8%). Adenovirus, human metapneumovirus 
and parechovirus were found in fewer than 2.5% of samples. Influenza virus was found in 15 
(2.3%) of which five were influenza A and ten were detected seven days after vaccination and 
so likely to represent vaccine virus (none of these children reported influenza-like-illness). We 
found no evidence for a difference in non-influenza viral detection rates between groups at 
baseline (table 1) or at visits 2 and 3 (22/66 and 24/64, p=0.859; 21/65 and 15/72, p=0.130, 
respectively). Rates of detection of rhinovirus, the most frequently detected virus, were also 
similar in both groups. 
 
Bacterial prevalence visits 1-3 
At baseline, carriage prevalence was high for S. pneumoniae, M. catarrhalis and H. influenzae 
(68.3%, 77.6% and 57.8% respectively) and lower for S. aureus (10.6%); there was no evidence 
to suggest a difference between the groups (table 2).  At V2 and V3 (7 and 28 days post early 
vaccination) there was no evidence to suggest a difference between the two study groups in 
the detection of these bacterial species apart from an apparent modest and transient increase 
in H. influenzae prevalence seen at V2. 46/66 (69.7%) were positive among the early vaccinees 
and 36/69 (52.2%) among the controls (p= 0.042, adjusted for clustering by nursery).  
 
Bacterial density visit 1-3 
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Changes in bacterial density were investigated in those children who were positive for carriage 
at baseline (V1).  Amongst these children, there was no evidence to suggest a difference in 
mean S. pneumoniae density (GC/ml) between the study groups at baseline (V1) or seven days 
(V2) after the intervention.  However, at V3 (28 days after vaccination) a six-fold higher mean 
bacterial density was found in children positive for carriage in the vaccinated group, whose 
values had risen compared to controls, whose values appeared to have fallen slightly over this 
period (table 3).  There was no evidence of a difference at either V2 or V3 (7 or 28 days after 
vaccination) for M. catarrhalis or H. influenzae; there were too few positive children for S. 
aureus at baseline to permit statistical analysis (n=15) although there was a trend towards 
higher density carriage in vaccinees (online supplement figure E1). 
 
 
Carriage over the whole study period 
At the first visit, 45 children tested negative for carriage of S. pneumoniae (samples at visit 1 
were unavailable for 9 children).  Over the course of the study 42 of these subsequently tested 
positive, including 9 children before receiving a vaccine, 20 after receiving 1 dose and 10 after 
receiving 2 doses with the three remaining children leaving the study.  Similarly to the findings 
of the between groups analysis, in the pre/post vaccine analysis across all visits there was little 
to suggest any differences in carriage prevalence after vaccination (one or two doses of LAIV) 
for S. pneumoniae, M. catarrhalis or S. aureus (table 4).  However, once again, there was 
evidence for an effect of vaccine to increase H. influenzae prevalence, with higher odds of 
carriage after both one and two doses of LAIV, after controlling for confounding and allowing 
for clustering by nursery and repeated measures on children over time.  Analyses of bacterial 
density were again restricted to those children with detectable carriage at baseline (in order to 
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assess changes in density as opposed to acquisition).  Again, there was evidence of an increase 
in S. pneumoniae density with increasing doses of vaccine, in particular a 2.5 fold increase in 
density was observed after 2 vaccine doses, compared to pre-vaccine levels, when considering 
samples over all time points in the study (table 5).  There was also evidence of vaccine-
associated increases in M. catarrhalis density in carriers with a more than doubling observed 
after the first vaccine dose.  Although point estimates post-vaccine were also raised relative to 
pre-vaccine values for H. influenzae, the confidence intervals were wide.  Again too few 
children were carriers of S. aureus to permit analysis of density by this approach.  The 
relationship between nasal discharge scores (SNOT score) and bacterial density was 
investigated by including nasal discharge scores in the S. pneumoniae model and evidence was 
found for an independent positive association with pneumococcal density (online supplement 
table E3). 
 
Discussion 
This is the first study to explore the effects of experimental respiratory viral infection upon 
bacterial upper respiratory colonization in humans. We show that infections with attenuated 
viruses can result in increases in carriage density of common bacteria or increases in 
acquisition, raising the possibility that wild type influenza and other viruses may have more 
marked such effects. Children carrying more bacteria are probably more infectious than those 
with fewer and it makes biological sense that such bacteria should evolve to sense viral rhinitis 
or the host response to it and exploit it as a transmission opportunity. In addition to 
proliferating, bacteria might change phenotype to one better suited to successful transit. Our 
findings also suggest that LAIV could be used as an experimental tool with which to elucidate 
relationships between nasal bacterial abundance and transmission rates between children. 
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Since the effectiveness of pneumococcal conjugate vaccines depends upon their impact on 
bacterial transmission both within and beyond the pediatric population, there are good 
practical reasons why the biology of this process should be elucidated in detail. 
 
Does this study raise safety concerns about LAIV? We did not detect any safety signals 
associated with increased bacterial colonization density but the study was not powered to do 
so. Upper respiratory carriage of bacteria is not an illness and many authors assume it to be 
asymptomatic(22, 23). We have reported an association between carriage of H. influenzae and 
rhinitis in healthy children(4) and here we demonstrate an association for S. pneumoniae 
density independent of detectable viral nucleic acid and age. However, these symptoms are 
mild and the vaccine has been studied in clinical trials(10-13) and widely used in children aged 
2 years and older without any safety signals which one might attribute to higher bacterial 
density such as otitis media, pneumonia or bacteremia and overall the vaccine protects against 
the former(10). One might expect evolutionary pressures to select for bacteria which exploit 
the ubiquitous respiratory viral infections of early childhood to promote colonization and 
transmission while minimizing serious pathology in their hosts.  
 
An apparent short term effect of LAIV on carriage prevalence of H. influenzae in the 
randomized comparison was confirmed in multivariable analysis where it was also observed for 
the second vaccine dose. However measurement of colonization rates with this and other 
bacterial species was not the primary study aim and absolute numbers of carriers constituting 
the difference were small, so it is possible that this finding may have occurred by chance.  If it is 
a genuine increase in bacterial acquisition induced by the vaccine, it has echoes of the 
observation of pneumococcal acquisition in ferrets experimentally infected with influenza (2). 
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In a recent adult pneumococcal challenge study, colonization was more likely in the presence 
of a respiratory virus(24) although this was not associated with higher carriage density, 
possibly reflecting differences between adults and children. Confirmatory studies of acquisition 
of H. influenzae and other bacterial species are needed. A twofold rise in M. catarrhalis density 
was seen in the comparison of pre- and post-vaccine doses but not in the randomized 
comparison most likely due to a population average effect (specifically, the big impact of those 
with very high colonization densities). We also found that colonization at the time of 
vaccination is associated with greater overall rises in density, suggesting that increases in 
bacterial load were not due to acquisition of new strains but proliferation of those already 
present (data not shown). This could be confirmed in future studies. We also found no effects 
of number of siblings (table 1) on the observed differences between groups (data not shown). 
There were too few S. aureus carriers to analyze the effects of the vaccine on density, although 
we saw apparently similar rises in density at V3 (28 days) those seen for S. pneumoniae (online 
supplement, figure E1) observations concordant with those made in animal models(15). 
 
More generally, the use of randomization and the blinding of the laboratory analysis make it 
unlikely that our results were subject to bias or confounding and the size of the effects seen 
were sufficiently large to allow for possible biological effects on transmission rates. Although 
several bacterial species were studied, increasing the possibility of apparent differences arising 
by chance, individual upwards trends were consistently seen while secondary larger non-
randomized but conservative multivariable analysis re-confirmed the positive findings of the 
randomized comparisons and extended them to other species when potential confounding 
factors, in particular age and clustering by nurseries, were taken into account.  
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The stepped wedge design used reduced the time period over which randomized comparisons 
could be made but allowed more children and samples to be included in a confirmatory pre- 
post-vaccine multivariate analysis and had the ethical and practical advantage of offering all 
participants protection against influenza. The higher drop-out rate in the early vaccine group 
was mostly evident after the third visit (figure 1) and thus did not influence the findings of the 
between group analysis (V1-3). That no placebo was used is a limitation but an administration 
device identical to the vaccine could not be obtained. Less than 30% of the available parents 
consented to participate which is high for a pediatric vaccine study, but raises the possibility of 
selection bias. We could not collect information on parents who refused or their children and 
so cannot exclude this possibility but have no reason to believe our subjects were 
unrepresentative of the population.  
Our estimate of the effect of LAIV on bacterial carriage may be conservative. Available 
resources permitted us to conduct an individually randomized study. Through exposure to 
vaccinated children with elevated rates or density of colonization, controls may have also had 
their values elevated diluting the observed effect of the intervention. Future confirmatory 
studies would preferably have a cluster randomized design.  
 
We detected and quantified species-specific bacterial DNA using PCR rather than viable 
bacteria by conventional culture techniques and thus will, in part, have been detecting DNA 
from non-viable organisms. Had cultures been done, doubtless some PCR-positive culture-
negative individuals would have been found. However, we have recently shown that 
individuals with discordant PCR and culture results tend to have low density colonization(16). 
Although DNA may be present in the absence of living organisms, it nevertheless represents a 
footprint of recent bacterial presence and that is what this study was designed to measure. 
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Nevertheless it will be important to perform follow up confirmatory studies and to elucidate 
how the bacterial density measurements we report here relate to efficiency of transmission 
between colonized children.  
 
Based on murine studies(15) our expectation was that changes in nasal bacterial colonization 
density would be evident around seven days after immunization and our observations of 
increases at 28 days were unexpected raising questions about the time course of this effect in 
children. As no intermediate samples between 7 and 28 days were taken, nor any more than 
28 days after a vaccine dose, the timing of the peak of this effect remains unclear. Since 
bacteria can divide very rapidly, one can speculate that the time lag that rendered the density 
rise undetectable at 7 days, by when vaccine viral infection would have been well established, 
indicates that bacterial proliferation is triggered by the host response rather than the viruses 
themselves. It is also possible that the usually asymptomatic infections caused by attenuated 
cold-adapted vaccine viral strains induce relatively slow, small bacterial responses that were 
hard to detect at the earlier time point. Future studies should include additional sampling 
times to clarify the duration of this effect and the timing of its peak. 
Although we present results on several bacterial species which commonly colonize children, we 
offer no information about serotypes of the studied species or the many others which are 
commonly present (25). We are now undertaking further analysis of these samples using 
microbiomic techniques to further explore viral-bacterial interactions. 
 
In conclusion, we show that viral infections may induce species-specific changes both in 
bacterial density and acquisition and that it is important to study bacterial colonization as a 
continuous variable. Although not associated with disease, these effects may be important at 
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the population level especially in the context of more virulent wild-type respiratory virus 
infections which may have potent effects on bacterial transmission between individuals. Nearly 
all childhood vaccination programs rely to an extent upon the interruption of transmission of 
infections, so our findings should encourage further human studies of transmission dynamics.  
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Figure legends 
Figure 1. Study Consort flow diagram 
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Tables 
 
 
Table 1. Clinical characteristics of the two study groups at randomization 
 
Vaccine  
n=74* 
Controls 
n=77 
p 
Age (months) 38.3 (7.8) 40.3 (6.7) 0.11 
Male  35/74 (47.3) 37/77 (48.1) 0.93 
Mean number of siblings 0.69 (0.77) 1.04 (1.02) 0.02 
Underlying medical condition 11/74 (14.9) 17/77 (22.1) 0.25 
Parental smoking 6/73 (8.2) 5/74 (6.8) 0.74 
National vaccination schedule not 
complete 
2/73 (2.7) 1/77 (1.3) 0.53 
Given influenza vaccine - previous 2 
seasons 
4/73 (5.5) 3/75 (4.0) 0.67 
Non-influenza viral nucleic acid detected 24/69 21/71 0.512 
*Values are mean (standard deviation) or n/N (percentage) 
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Table 2. Carriage prevalence of bacterial species in early vaccine and control groups by visit 
 
S. pneumoniae M. catarrhalis H. influenzae S. aureus 
 
Children with 
carriage n/N (%) OR    
(95% CI)* 
p 
Children with 
carriage n/N (%) OR     
(95% CI) 
p 
Children with 
carriage n/N (%) OR    
(95% CI) 
p 
Children with 
carriage n/N (%) OR    
(95% CI) 
p 
 
Controls Vaccine Controls Vaccine Controls Vaccine Controls Vaccine 
Visit 1  
(baseline) 
51/72 
(70.8) 
46/70 
(65.7) 
0.79  
(0.39 to 
1.60) 
0.512 
52/66 
(78.8) 
52/68 
(76.5) 
0.90 (0.39 
to 2.08) 
0.810 
39/72 
(54.2) 
43/70 
(61.4) 
1.36 
(0.69 to 
2.66) 
0.376 
8/72 
(11.1) 
7/70 
(10.0) 
0.89  
(0.30 to 
2.63) 
0.836 
Visit 2  
(+/-7 days) 
48/69 
(69.6) 
45/66 
(68.2) 
0.94 
(0.45 to 
1.94) 
0.862 
56/66 
(84.9) 
54/66 
(81.8) 
0.80 
(0.32 to 
2.01) 
0.641 
36/69 
(52.2) 
46/66 
(69.7) 
2.13 
(1.03 to 
4.44) 
0.042 
5/69 
(7.3) 
4/66 
(6.1) 
0.83 
(0.21 to 
3.30) 
0.792 
Visit 3  
(+/-28 days) 
52/72 
(72.2) 
41/65 
(63.1) 
0.66 
(0.32 to 
1.36) 
0.255 
52/68 
(76.5) 
50/65 
(76.9) 
1.01 
(0.45 to 
2.28) 
0.983 
47/72 
(65.3) 
44/64 
(68.8) 
1.19 
(0.57 to 
2.48) 
0.639 
5/72 
(6.9) 
7/65 
(10.8) 
1.62  
(0.49 to 
5.37) 
0.433 
*OR of carriage at each visit in early vaccine group compared to control group with nursery (random effect, intercept) in the model. 
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Table 3. Carriage density of bacterial species in early vaccine and control groups, in individuals who were carriage positive at baseline  
 
S. pneumoniae M. catarrhalis H. influenzae 
 
Mean carriage* 
density GC/ml (SD) 
Mean 
ratio** 
(95% CI) 
p 
Mean carriage 
density  GC/ml (SD) 
Mean 
ratio 
(95% CI) 
p 
Mean carriage 
density GC/ml (SD) 
Mean 
ratio 
(95% CI) 
p 
 
Controls Vaccine Controls Vaccine Controls Vaccine 
Visit 1  
(baseline) 
3297 
(6394) 
2687 
(4635) 
0.78 
(0.38 to 
1.61) 
0.501 
15399 
(58725) 
13673 
(40268) 
0.91 
(0.38 to 
2.19) 
0.830 
17286 
(38941) 
18379 
(41310) 
1.11 
(0.39 to 
3.20) 
0.846 
Visit 2  
(7 days) 
3484 
(9640) 
4202 
(8481) 
1.81 
(0.81 to 
4.04) 
0.146 
19589 
(90043) 
19871 
(42525) 
1.82 
(0.78 to 
4.27) 
0.165 
10505 
(19159) 
29985 
(73937) 
2.19 
(0.76 to 
6.30) 
0.145 
Visit 3  
(28 days) 
1935 
(5275) 
16687 
(56920) 
6.35 
(2.30 to 
17.61) 
<0.001 
25597 
(83640) 
18640 
(42995) 
0.92 
(0.38 to 
2.20) 
0.845 
26858 
(96327) 
24550 
(46652) 
2.15 
(0.73 to 
6.34) 
0.167 
*Mean carriage density in those who were positive.  SD: standard deviation.  **Arithmetic mean ratio. Estimates of arithmetic mean ratio 
allows for clustering by nursery (random effect, intercept) and so is not the simple quotient of the respective means. Too few children carried 
S. aureus for statistical analysis. 
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Table 4. Odds ratios (generalized linear mixed models) for carriage prevalence of bacterial species after vaccination including all visits in 
modified intention-to-treat population 
 
S. pneumoniae M. catarrhalis H. influenzae S. aureus 
 
OR (95% CI)* p OR (95% CI)* P OR (95% CI)* p OR (95% CI)* p 
Unvaccinated 
1.00 
(Reference) 
0.777 
1.00 
(Reference) 
0.091 
1.00 
(Reference) 
0.015 
1.00 
(Reference) 
0.868 1 LAIV dose 
0.84 (0.52 to 
1.36) 
1.15 (0.62 to 
2.15) 
2.23 (1.29 to 
4.21) 
0.81 (0.34 to 
1.90) 
2 LAIV dose 
0.90 (0.44 to 
1.81) 
2.59 (0.94 to 
7.12) 
3.46 (1.33 to 
9.02) 
0.73 (0.20 to 
2.65) 
*OR of carriage adjusted by months of age, gender, presence of smoker in the home, number of siblings, 
presence of viral nucleic acid, time (week in the study) with nursery and subject ID as random effects (intercept). 
Data for the 2nd LAIV dose relate only to the group who received vaccine at visits 1 and 3. 
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Table 5. Arithmetic mean ratio (generalized linear mixed models) for carriage density of bacterial species after vaccination including all 
visits in modified intention-to-treat population 
 
S. pneumoniae M. catarrhalis H. influenzae 
 
Arithmetic 
mean ratio 
(95% CI)* 
p 
Arithmetic 
mean ratio 
(95% CI)* 
p 
Arithmetic 
mean ratio 
(95% CI)* 
p 
Unvaccinated 
1.00 
(Reference) 
0.064 
1.00 
(Reference) 
0.029 
1.00 
(Reference) 
0.161 1 LAIV dose 
1.24 (0.69 to 
2.23) 
2.21 (1.22 to 
4.00) 
1.89 (0.98 to 
3.65) 
2 LAIV dose 
2.68 (1.11 to 
6.47) 
1.99 (0.84 to 
4.73) 
1.69 (0.69 to 
4.17) 
* Arithmetic mean ratio (95% CI) of carriage density adjusted by months of age, gender, smoker in the home, number of siblings, presence of 
viral nucleic acid, time (week in the study) with nursery and subject ID as random effects (intercept). Too few children carried S. aureus for 
statistical analysis. Data for the 2nd LAIV dose relate only to the group who received vaccine at visits 1 and 3. 
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Figures 
Figure 1. Study Consort flow diagram 
 
 
 
 
659 eligible children 
151 randomized 
373 declined to participate/ 
did not respond to invite. 
    3 excluded due to severe 
asthma, egg allergy 
527 received 
information sheet 
132 children where 
parents could not be 
contacted 
74 allocated to early vaccine 
    4 needing 1 LAIV dose only 
    3 did not consent to vaccination 
77 allocated to control/ late vaccine 
    3 needing 1 LAIV dose only 
    1 did not consent to vaccination 
66 received LAIV (1st dose) 
70 swab taken 
4 withdrew consent 
72 swab taken 
3 not present/refused 
2 withdrew consent 
Visit 1 
Day 0 
66 swab taken 
2 not present/refused 
2 withdrew consent 
69 swab taken 
6 not present/refused 
0 withdrew consent 
Visit 2 
Day +/-7 
58 received LAIV (2nd dose) 
65 swab taken 
3 not present/refused 
0 withdrew consent 
70 received LAIV (1st dose) 
72 swab taken 
2 not present/refused 
1 withdrew consent 
Visit 3 
Day +/-28 
59 swab taken 
7 not present/refused 
2 withdrew consent 
69 swab taken 
4 not present/refused 
1 withdrew consent 
Visit 4 
Day +/-35 
60 swab taken 
6 not present/refused 
0 withdrew consent 
63 received LAIV (2nd dose) 
68 swab taken 
3 not present/refused 
2 withdrew consent  
Visit 5 
Day +/-56 
